FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020

Bookmark and Share
Published: 15 Jun 2020
Views: 4000
Prof Robert Huddart and Dr Ignacio Durán

Prof Robert Huddart (The Royal Marsden NHS Foundation Trust, Sutton, UK) and Dr Ignacio Durán (Marques de Valdecilla University Hospital, Santander, Spain) discuss the latest advances regarding testing and screening for FGFR alterations in bladder cancer, and highlight some relevant studies presented at the virtual ASCO 2020 meeting.

Prof Huddart provides an overview of the BLC2001 study, investigating erdafitinib in locally advanced or metastatic urothelial carcinoma.

Dr Durán describes the FORT-2 study, which examines the combination of rogaratinib and atezolizumab in patients with locally advanced or metastatic urothelial cancer and FGFR mRNA over-expression.

The experts go on to discuss how to test for these alterations, and the potential clinical impacts going forward. They also consider the use of liquid biopsies versus archival tissue, and the associated challenges with these methods.

Dr Durán concludes by discussing another study presented at ASCO 2020, assessing the use of infigratinib in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).